Silvia Novello membro Comitato Scientifico ICAPEM e Bonnie J ADDARIO Lung Cancer Foundation

La presidente di WALCE, Silvia Novello, è diventata

- Membro del Comitato Scientifico ICAPEM (Investigación sobre Cáncer de Pulmón en Mujeres )
- Membro del Comitato Scientifico Bonnie J ADDARIO Lung Cancer Foundation


La presidente di WALCE, Silvia Novello, è diventata membro del Comitato direttivo dello IASLC (International Association for the Study of Lung Cancer).

IASLC è la sola organizzazione mondiale dedicata allo studio del tumore del polmone. Fondata nel 1974, conta più di 3000 specialisti in 80 Paesi, un traguardo importantissimo per Walce, avere un membro del proprio direttivo all’interno dello IASLC.

dalle pagine del sito IASLC

The IASLC has worked since 1974 to promote research into all aspects of lung cancer and thoracic malignancies, as well as encouraging worldwide cancer prevention efforts. Some recent highlights include:

In 2000, IASLC published its Tokyo Declaration on Tobacco in 2000, urging governments to take action against the alarming rate at which lung cancer was occuring in men and women. In 2007, IASLC revised its Declaration on Tobacco, adding a recommendation that governments “initiate legislative action for ultimate elimination of manufacture and sales of tobacco products.”
In 2006, IASLC published its first statement on CT screening for lung cancer, based on preliminary results from the National Lung Screening Trial (NLST) in the United States. On July 4, 2011, IASLC revised its Statement on CT Screening for Lung Cancer to take into account new data and results from the NLST, as well as ongoing trials around the world.
In 2009, IASLC unveiled the International Staging Classification System for Lung Cancer, developed in collaboration with the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC). Although the TNM (tumor, node, metastasis) classification of malignant tumors had existed for decades, the 7th TNM revision used an international database developed with IASLC to broaden understanding of the clinical staging of lung cancer.
In 2011, IASLC published the International Multidisciplinary Classification of Lung Adenocarcinoma, the first revision to the classification in six years and the first to be developed by a multidisciplinary panel of experts. IASLC developed the classification with oversight from the American Thoracic Society and the European Respiratory Society.

I commenti sono chiusi.